Novartis
Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales
Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor
Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing
Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals
Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance
Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government
Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory
Novartis’ Kisqali Secures Broad FDA Approval for Adjuvant Treatment of Early Breast Cancer
Kisqali, Novartis, FDA Approval, Early Breast Cancer, Adjuvant Treatment, HR+/HER2- Breast Cancer, CDK4/6 Inhibitors
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis
Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration
Novartis Expands Radioligand Therapy Manufacturing with $200M Investment in Two US Sites
Novartis, radioligand therapy, manufacturing expansion, $200M investment, California, Indianapolis
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion